Correlation Between ZyVersa Therapeutics and Larimar Therapeutics
Can any of the company-specific risk be diversified away by investing in both ZyVersa Therapeutics and Larimar Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining ZyVersa Therapeutics and Larimar Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between ZyVersa Therapeutics and Larimar Therapeutics, you can compare the effects of market volatilities on ZyVersa Therapeutics and Larimar Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in ZyVersa Therapeutics with a short position of Larimar Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of ZyVersa Therapeutics and Larimar Therapeutics.
Diversification Opportunities for ZyVersa Therapeutics and Larimar Therapeutics
0.5 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between ZyVersa and Larimar is 0.5. Overlapping area represents the amount of risk that can be diversified away by holding ZyVersa Therapeutics and Larimar Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Larimar Therapeutics and ZyVersa Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on ZyVersa Therapeutics are associated (or correlated) with Larimar Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Larimar Therapeutics has no effect on the direction of ZyVersa Therapeutics i.e., ZyVersa Therapeutics and Larimar Therapeutics go up and down completely randomly.
Pair Corralation between ZyVersa Therapeutics and Larimar Therapeutics
Given the investment horizon of 90 days ZyVersa Therapeutics is expected to generate 1.55 times more return on investment than Larimar Therapeutics. However, ZyVersa Therapeutics is 1.55 times more volatile than Larimar Therapeutics. It trades about -0.07 of its potential returns per unit of risk. Larimar Therapeutics is currently generating about -0.12 per unit of risk. If you would invest 234.00 in ZyVersa Therapeutics on October 8, 2024 and sell it today you would lose (109.00) from holding ZyVersa Therapeutics or give up 46.58% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Weak |
Accuracy | 100.0% |
Values | Daily Returns |
ZyVersa Therapeutics vs. Larimar Therapeutics
Performance |
Timeline |
ZyVersa Therapeutics |
Larimar Therapeutics |
ZyVersa Therapeutics and Larimar Therapeutics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with ZyVersa Therapeutics and Larimar Therapeutics
The main advantage of trading using opposite ZyVersa Therapeutics and Larimar Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if ZyVersa Therapeutics position performs unexpectedly, Larimar Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Larimar Therapeutics will offset losses from the drop in Larimar Therapeutics' long position.ZyVersa Therapeutics vs. Cns Pharmaceuticals | ZyVersa Therapeutics vs. Immix Biopharma | ZyVersa Therapeutics vs. Hepion Pharmaceuticals | ZyVersa Therapeutics vs. Zura Bio Limited |
Larimar Therapeutics vs. Vaxcyte | Larimar Therapeutics vs. Syndax Pharmaceuticals | Larimar Therapeutics vs. Merus BV | Larimar Therapeutics vs. Sutro Biopharma |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Complementary Tools
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation |